Fixed-duration ibrutinib plus venetoclax may benefit patients with high-risk chronic lymphocytic leukemia
by American Association for Cancer ResearchCredit: CC0 Public DomainFirst-line ibrutinib (Imbruvica) plus venetoclax (Venclexta) led to high response and survival rates in patients with chronic l
Updated on: January 30,2024
14

Fixed-duration ibrutinib plus venetoclax may benefit patients with high-risk chronic lymphocytic leukemia
by American Association for Cancer ResearchCredit: CC0 Public DomainFirst-line ibrutinib (Imbruvica) plus venetoclax (Venclexta) led to high response and survival rates in patients with chronic l
Updated on:January 30,2024
14
